Last checked at 25 Jul 2012 07:00
Oxford BioMedica: Notice of Interim Results
-- Results date: 31 August 2012 --
Oxford, UK - 25 July 2012: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, today announces that it will be releasing its interim results for the six months ended 30 June 2012 on Friday, 31 August 2012.
An analyst briefing will be held at 09:30am GMT on Friday, 31 August 2012 at the offices of M:Communications, 11th Floor, CityPoint, 1 Ropemaker Street, London, EC2Y 9AW. An audio replay will be available shortly afterwards via the Company's website at www.oxfordbiomedica.co.uk.
- Ends -
For further information, please contact: |
|
Oxford BioMedica plc: Lara Mott, Head of Corporate Communications | Tel: +44 (0)1865 783 000 |
Media Enquiries: Mary Clark/Sarah Macleod/Claire Dickinson M:Communications |
Tel: +44 (0)20 7920 2360
|
Notes to editors
1. Oxford BioMedica®
Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk.